Biomarkers in Urticaria

Urticaria is a heterogeneous mast-cells driven disease that is characterized by typical transient erythematous skin swelling with or without angioedema. Despite better knowledge and understanding of pathophysiological mechanisms, there are still areas that present challenges. Diseases duration is very unpredictable, the aetiology is often unknown and response to therapy is variable. Over the past years a lot of research has been done in urticaria biomarkers. However, no recommended biomarkers in practice have been established.

Considering different phenotypes and endotypes of chronic urticaria, there is a growing need to identify reliable biomarkers that could help us distinguish between different clinical phenotypes, reflect endotypes and guide treatment decisions. The aim of this Research Topic is to explore and expand current knowledge on biomarkers in chronic urticaria that can help assess disease activity and severity, predict disease duration and treatment response with a focus on the biomarkers that can be potentially used in clinical practice.

Suitable themes for manuscripts include:
- Biomarkers of disease activity, severity and disease duration
- Biomarkers of therapy response
- Recommendation of biomarkers in clinical practice

All types of articles accepted by Frontiers in Allergy are welcome.

Keywords: urticaria, biomarkers, disease activity, disease duration, therapy

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.